Marconi Richard T, Garcia-Tapia David, Hoevers Jacquelien, Honsberger Nicole, King Vickie L, Ritter Dianne, Schwahn Denise J, Swearingin Leroy, Weber Angela, Winkler M Teresa C, Millership Jason
Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond, VA 23298-0678, United States.
Zoetis Inc., 333 Portage Road, Kalamazoo, MI 49007-4931, United States.
Vaccine X. 2020 Oct 9;6:100079. doi: 10.1016/j.jvacx.2020.100079. eCollection 2020 Dec 11.
Lyme disease, a public health threat of significance to both veterinary and human medicine, is caused by the tick () transmitted spirochete, . Here we report on the immunogenicity and efficacy of VANGUARD®crLyme (Zoetis), the most recent canine Lyme disease vaccine to be approved by the United States Department of Agriculture. VANGUARD®crLyme is a subunit vaccine consisting of outer surface protein A (OspA) and a recombinant outer surface protein C (OspC) based-chimeric epitope protein (chimeritope) that consists of at least 14 different linear epitopes derived from diverse OspC proteins. The combination of OspA and the OspC chimeritope (Ch14) in the vaccine formulation allows for the development of humoral immune responses that work synergistically to target spirochetes in both ticks and in mammals. Immunogenicity was assessed in purpose-bred dogs. A two-dose vaccination protocol resulted in high antibody titers to OspA and Ch14 and vaccinal antibody reacted with 25 different recombinant OspC variants. Efficacy was demonstrated using an -purpose bred dog challenge model. Vaccination with VANGUARD®crLyme provided protection against infection and prevented the development of clinical manifestations and histopathological changes associated with Lyme disease.
莱姆病对兽医和人类医学来说都是一种重大的公共卫生威胁，它由蜱传播的螺旋体引起。在此，我们报告美国农业部最近批准的犬用莱姆病疫苗VANGUARD®crLyme（硕腾公司生产）的免疫原性和效力。VANGUARD®crLyme是一种亚单位疫苗，由外表面蛋白A（OspA）和基于重组外表面蛋白C（OspC）的嵌合表位蛋白（嵌合表位）组成，该嵌合表位由至少14种源自不同OspC蛋白的不同线性表位组成。疫苗配方中OspA和OspC嵌合表位（Ch14）的组合能够产生体液免疫反应，协同作用以靶向蜱和哺乳动物体内的螺旋体。在定向培育的犬只中评估了免疫原性。两剂接种方案导致对OspA和Ch14产生高抗体滴度，并且疫苗抗体与25种不同的重组OspC变体发生反应。使用定向培育的犬只攻毒模型证明了效力。用VANGUARD®crLyme疫苗接种可提供抗感染保护，并预防与莱姆病相关的临床表现和组织病理学变化的发展。
